Drugs / BY002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07640438 | Jun → Nov 2026 expected | — | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| Phase 1 | NCT07270770 | Mar 2026 → Mar 2027 expected | acute leukemia | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BY002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07640438 ↗ |
| Action | Inhibit | “BY002 is a selective menin inhibitor developed in China.” NCT07270770 ↗ |
| Route | Oral | “BY002 is administered orally in 28-day cycles until disease progression, unacceptable toxicity, HSCT, withdrawal, or death.” NCT07270770 ↗ |